The first tumor digital therapy class II syndrome is coming! Zero krypton & Zhongxi's early lung cancer postoperative rehabilitation products were approved

On April 28, yiouda health learned that recently, after going through the processes of product design and R & D, clinical effectiveness verification, classification definition, registration and testing, system assessment, review and approval, Zhongxi medical technology (original digital healing medical technology), a subsidiary of zero krypton technology, successfully won the first certificate of digital therapy in the field of cancer in China with its first digital therapy product th-002. Th-002 approved this time is mainly for patients with early postoperative lung cancer, providing personalized out of hospital rehabilitation treatment scheme, and the concept of Epro (electronic patient reporting clinical outcome) and the practice of eras (accelerated rehabilitation surgery) are implemented. The product can automatically adjust and generate the task of the next day according to the patient's baseline and daily treatment completion. At present, the overall compliance of patients with this product is stable at more than 80%, and the survival benefit is significantly improved. Last year, led by Professor Sun Daqiang of thoracic surgery of Tianjin chest hospital and Professor Chen Pingyan of Biostatistics Department of Hainan real world data research institute and Southern Medical University, it was the first multi center, observational The results of long-term follow-up of patients with large sample volume (11958 cases) with stage Ⅰ ~ Ⅲ a non-small cell lung cancer (NSCLC) showed that the active participation in follow-up increased the 5-year survival rate to 81.8% (74.2% in passive follow-up), and the survival benefit of stage Ⅲ a patients was more obvious. The active follow-up design in this study is based on the digital therapy logic of Zhongxi medical technology, such as patient review, drug use, adverse reaction treatment and so on.